Skip to main content

OncoCyte Corporation (OCX)

NASDAQ: OCX · IEX Real-Time Price · USD
3.52 0.18 (5.39%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap309.41M
Revenue (ttm)4.21M
Net Income (ttm)-27.50M
Shares Out89.76M
EPS (ttm)-0.36
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume275,314
Open3.34
Previous Close3.34
Day's Range3.34 - 3.54
52-Week Range1.41 - 6.57
Beta1.91
AnalystsStrong Buy
Price Target9.00 (+155.7%)
Est. Earnings DateNov 11, 2021

About OCX

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic...

IndustryBiotechnology
Founded2009
Employees51
Stock ExchangeNASDAQ
Ticker SymbolOCX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for OncoCyte stock is "Strong Buy." The 12-month stock price forecast is 9.00, which is an increase of 155.68% from the latest price.

Price Target
$9.00
(155.68% upside)
Analyst Consensus: Strong Buy

News

Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insig...

2 weeks ago - GlobeNewsWire

Oncocyte Publishes Study Demonstrating Predictive Potential for DetermaIO® Test in Triple Negative Breast Cancer

Data show that DetermaIO demonstrates superior accuracy compared to standard of care PD-L1 IHC for predicting a patient's response to immunotherapy Data show that DetermaIO demonstrates superior accurac...

3 weeks ago - GlobeNewsWire

Why Stocks Are Down Today & 3 Penny Stocks To Watch Now

Penny stocks climbing higher even with stocks down today. The post Why Stocks Are Down Today & 3 Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock...

Other symbols:KULRTUEM
1 month ago - PennyStocks

Oncocyte Announces Oral Presentation of New Data on Its DetermaIO™ Immunotherapy Response Test at the European Societ...

Randomized clinical trial data from NeoTRIPaPDL1 study establishes DetermaIO as a predictive biomarker of immunotherapy response

1 month ago - GlobeNewsWire

Modern Healthcare Recognizes Oncocyte as One of the 2021 Best Places to Work in Healthcare

CHICAGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights th...

1 month ago - GlobeNewsWire

Oncocyte to Participate in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference

IRVINE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insi...

1 month ago - GlobeNewsWire

Is the Options Market Predicting a Spike in OncoCyte (OCX) Stock?

Investors need to pay close attention to OncoCyte (OCX) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Oncocyte Launches First Real-World Evidence (RWE) Registry to Evaluate Biomarker Impact on Early-Stage Lung Cancer Tr...

P redictive A ssay for D ecision M aking in A djuvant T herapy (PADMA) Registry to enroll more than 1,000 patients at 25 major hospitals treating lung cancer in the United States beginning Q4 2021

2 months ago - GlobeNewsWire

Oncocyte Shares Fall On Posting Wider Than Expected Q2 Loss

Oncocyte Corporation's (NASDAQ: OCX) Q2 revenues were $2.03 million, compared to $143,000 in Q2 FY20 and beating consensus of $1.57 million. Most revenues were attributable to tech transfer under a Dece...

2 months ago - Benzinga

OncoCyte (OCX) Reports Q2 Loss, Tops Revenue Estimates

OncoCyte (OCX) delivered earnings and revenue surprises of 0.00% and 23.40%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Oncocyte Reports Second Quarter 2021 Financial Results and Provides Corporate Update

DetermaRx Q2 Sample Volume Grows 23% over Q1 2021

2 months ago - GlobeNewsWire

Oncocyte to Participate in Upcoming Investor Events

IRVINE, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insig...

2 months ago - GlobeNewsWire

Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know

OncoCyte (OCX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10

IRVINE, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insig...

2 months ago - GlobeNewsWire

10 Best Stocks for 2021: Where Do Things Stand Halfway Through the Year?

After the end of the second quarter, let's take a look at where things stand in the InvestorPlace Best Stocks for 2021 contest. The post 10 Best Stocks for 2021: Where Do Things Stand Halfway Through th...

2 months ago - InvestorPlace

Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on

Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.

Other symbols:CRDFCTLTNVCRNVSPKI
3 months ago - Zacks Investment Research

EchelonDx and Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical T...

RENO, Nev.--(BUSINESS WIRE)--Echelon Diagnostics and Oncocyte join forces to develop analytical software that can scale to support Oncocyte's clinical tests and solutions

4 months ago - Business Wire

Oncocyte Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocyte's DetermaIO Test in Color...

Gruppo Oncologico del Nord Ovest, a Leading European Clinical Trials Group, Conducts Independent Investigator-Sponsored Clinical Trials for Pharmaceutical Targeted and Immune Therapies

4 months ago - GlobeNewsWire

Oncocyte Reports First Quarter 2021 Financial Results and Provides Corporate Update

-Oncocyte Q1 revenues beat consensus estimate, driven by strong DetermaRx and Pharma Services growth -

5 months ago - GlobeNewsWire

Oncocyte to Report First Quarter 2021 Financial Results on Monday, May 17

IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the c...

5 months ago - GlobeNewsWire

Will OncoCyte (OCX) Report Negative Q1 Earnings? What You Should Know

OncoCyte (OCX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Oncocyte to Present New Data on DetermaIO™ Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the ...

DetermaIO now shown to predict immunotherapy response in four different tissue types suggesting potential pan-cancer applicability DetermaIO now shown to predict immunotherapy response in four different...

5 months ago - GlobeNewsWire

Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix B...

Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant rejection testing, both from a standard blood sample

6 months ago - GlobeNewsWire

Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoi...

IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the...

6 months ago - GlobeNewsWire

Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential fo...

Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer

6 months ago - GlobeNewsWire